FT576 in Subjects With Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Scientists are testing a new drug called FT576 to see if it can help people with a type of cancer called multiple myeloma. They will give different amounts of the drug to small groups of people to figure out the best dose. Then, they will study more people to see if the drug works better when combined with another drug called daratumumab.
Scientists are testing a new drug called FT576 to see if it can help people with a type of cancer called multiple myeloma. They will give different amounts of the drug to small groups of people to figure out the best dose. Then, they will study more people to see if the drug works better when combined with another drug called daratumumab.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: